Clinical Trial Results:
An Open-Label, Multi-Centre, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents (12 to 17 years) with Asthma
Summary
|
|
EudraCT number |
2019-001259-37 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
09 Jul 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Dec 2020
|
First version publication date |
31 Dec 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
D3741C00012
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03976869 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
AstraZeneca AB
|
||
Sponsor organisation address |
Not applicable, Sodertalje, Sweden, SE-151 85
|
||
Public contact |
Clinical Study Information Center, AstraZeneca, US 1 877 240 9479, Information.Center@astrazeneca.com
|
||
Scientific contact |
Clinical Study Information Center, AstraZeneca, US 1 877 240 9479, Information.Center@astrazeneca.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-001976-PIP02-18 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
11 Sep 2020
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Jul 2020
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Jul 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Main objective of the study was to assess the pharmacokinetic (PK) profile of velsecorat (AZD7594) at steady state in adolescent subjects with asthma.
|
||
Protection of trial subjects |
The study protocol and all protocol amendments, all versions of the informed consent form (ICFs) and any other written information and/or materials provided to the subjects were submitted to an institutional review board (IRB) by the Investigator and approved by an IRB in writing before the study was initiated. This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)/ Good Clinical Practice (GCP), applicable regulatory requirements and the AstraZeneca policy on Bioethics. The Principal Investigator (PI) at each site ensured that subjects and their legally authorised representative, defined are their parents/legal guardians (caregiver), were given full and adequate oral and written information about the nature, purpose, possible benefit and risk of the study. The PI also notified subjects and caregivers that they were free to withdraw from the study at any time. The PI gave the subjects and caregivers the opportunity to ask questions and time to consider the information provided. Subjects and their legally authorised representatives were required to sign a statement of assent or informed consent, respectively, that met the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act requirements, where applicable, and the IRB or study centre.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
24 Jul 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 36
|
||
Worldwide total number of subjects |
36
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
36
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
The study was conducted in 10 centres across United States from 24-Jul-2019 to 9-Jul-2020. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Total 59 subjects were screened, 12 subjects were screen failed before entering the wash-out period and 11 subjects were screen failed after having entered the wash-out period. Finally 36 subjects entered the Treatment period and received velsecorat. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
12-14 years | ||||||||||||||||||
Arm description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via dry powder inhaler [DPI]) once daily for 15 to 16 days. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Velsecorat
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Inhalation powder
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Oral inhalation of velsecorat (360 µg [delivered dose], via dry powder inhaler [DPI]) once daily multiple-dose for 15 to 16 days. One inhalation per day at the same time (±30 minutes) every day.
|
||||||||||||||||||
Arm title
|
15-17 years | ||||||||||||||||||
Arm description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via DPI) once daily for 15 to 16 days. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Velsecorat
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Inhalation powder
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Oral inhalation of velsecorat (360 µg [delivered dose], via DPI) once daily multiple-dose for 15 to 16 days. One inhalation per day at the same time (±30 minutes) every day.
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
12-14 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via dry powder inhaler [DPI]) once daily for 15 to 16 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
15-17 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via DPI) once daily for 15 to 16 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
12-14 years
|
||
Reporting group description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via dry powder inhaler [DPI]) once daily for 15 to 16 days. | ||
Reporting group title |
15-17 years
|
||
Reporting group description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via DPI) once daily for 15 to 16 days. |
|
|||||||||||||
End point title |
Maximum observed plasma concentration at steady state (Cmax,ss) at Day 15 [1] | ||||||||||||
End point description |
To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was available for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Minimum observed plasma concentration at steady state within 0 to 12 hours (Cmin,ss) at Day 15 [2] | ||||||||||||
End point description |
To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was available for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Observed trough plasma concentration at end of dosing interval (τ) (Ctrough) at Day 15 [3] | ||||||||||||
End point description |
To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was available for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Time of maximum observed plasma concentration at steady state (tmax,ss) at Day 15 [4] | ||||||||||||
End point description |
To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was available for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Area under the plasma concentration-time curve over a dosing interval (τ) at steady state (AUCτ) at Day 15 [5] | ||||||||||||
End point description |
To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was available for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Area under the plasma concentration-time curve from time zero to 12 hours post-dose (AUC0-12) at Day 15 [6] | ||||||||||||
End point description |
To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was available for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Apparent total body clearance after extravascular administration at steady state (CLss/F) at Day 15 [7] | ||||||||||||
End point description |
To assess the PK profile of velsecorat at steady state following daily inhalations for 2 weeks in adolescent subjects with asthma. The PK analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of study drug and for whom at least 1 of the primary PK parameters was calculated, and who had no major protocol deviations considered to impact on the analysis of the PK data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and 15, 30 minutes, 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
Notes [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was available for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Area under the plasma cortisol concentration-time curve from 0 to 12 hours (AUEC0-12) | ||||||||||||
End point description |
To evaluate the pharmacodynamic (PD) of velsecorat following daily inhalations for 2 weeks in adolescent subjects with asthma. Baseline plasma cortisol concentration was determined during the washout period within 1-7 days before the first dose of study treatment. Change from baseline was calculated as the differences between the post-dose value at each time-point and baseline. The PD analysis set was used to evaluate this endpoint, which included all subjects for whom plasma cortisol AUEC0-12 was calculated at baseline and post-baseline, and who had no major protocol deviations considered to impact on the analysis of the PD data (e.g., disallowed medication, poor treatment compliance).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Pre-dose (baseline) and 2, 4, 6, 8, 12 hours post-dose at Day 15
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Plasma cortisol level on Day 15 | ||||||||||||
Statistical analysis description |
Relative change from baseline
|
||||||||||||
Comparison groups |
12-14 years v 15-17 years
|
||||||||||||
Number of subjects included in analysis |
28
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[8] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Geometric least squares mean | ||||||||||||
Point estimate |
0.92
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.79 | ||||||||||||
upper limit |
1.06 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.08
|
||||||||||||
Notes [8] - Statistical analyses of the change from baseline in plasma cortisol level on Day 15. Analyses were based on an analysis of covariance (ANCOVA) model with age group as fixed effect, and log-transformed baseline value as a covariate. |
|
|||||||||||||
End point title |
Change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15 | ||||||||||||
End point description |
To evaluate the PD of velsecorat following daily inhalations for 2 weeks in adolescent subjects with asthma. Baseline was defined as the mean of the two measured values before first study drug administration (-45 minutes and -15 minutes) on Day 1 and trough value was defined as the mean of the two measurements 30 minutes apart (23 hours after last dose) pre-dose on Day 15. This could be performed either at home (or other safe location of the subject’s choice) or at the study site. Safety analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of velsecorat.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 (baseline) and at Day 15 (pre-dose)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
FEV1 on Day 15 | ||||||||||||
Statistical analysis description |
Change from baseline
|
||||||||||||
Comparison groups |
12-14 years v 15-17 years
|
||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[9] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Least squares mean | ||||||||||||
Point estimate |
-0.05
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.17 | ||||||||||||
upper limit |
0.07 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.07
|
||||||||||||
Notes [9] - Statistical analyses of the change from baseline in morning trough FEV1 on Day 15. Analyses were based on ANCOVA model with age group as fixed effect, and baseline value as a covariate. |
|
|||||||||||||
End point title |
Change from baseline in asthma control questionnaire (ACQ-5) on Day 15 | ||||||||||||
End point description |
To evaluate the PD of velsecorat following daily inhalations for 2 weeks in adolescent subjects with asthma. Baseline and Day 15 ACQ-5 scores were defined as the mean of the five question responses collected before velsecorat administration at each of Day 1 and Day 15, respectively. Change from baseline was defined as the Day 15 score minus baseline score. The validated ACQ-5 measures both the adequacy of asthma control and changes in asthma control. The questionnaire had 5 items; each item is scored on a scale of 0 to 6, where lower scores corresponds better asthma control and higher scores represents more severe impairment/symptoms. Safety analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of velsecorat.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Day 15
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
ACQ-5 score on Day 15 | ||||||||||||
Statistical analysis description |
Change from baseline
|
||||||||||||
Comparison groups |
12-14 years v 15-17 years
|
||||||||||||
Number of subjects included in analysis |
34
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
[10] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Least squares mean | ||||||||||||
Point estimate |
-0.21
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.41 | ||||||||||||
upper limit |
-0.02 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.11
|
||||||||||||
Notes [10] - Statistical analyses of the change from baseline in ACQ-5 score on Day 15. Information regarding safety analysis sin second sentence. Analyses are based on ANCOVA model with age group as fixed effect, and baseline value as a covariate. |
|
|||||||||||||||||||||||||
End point title |
Number of subjects with adverse events (AEs) | ||||||||||||||||||||||||
End point description |
To evaluate the tolerability and safety of inhaled velsecorat. Safety analysis set was used to evaluate this endpoint, which included all subjects who took at least 1 dose of velsecorat.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Day 1 until follow-up (7-14 days)
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Day 1 until follow-up (7-14 days)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
21.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
15-17 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via DPI) once daily for 15 to 16 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
12-14 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received oral inhalation of velsecorat (360 µg, delivered dose, via dry powder inhaler [DPI]) once daily for 15 to 16 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
30 Oct 2019 |
Inclusion criteria #3 and #7 updated to clarify that asthma treatment may be daily or intermittently, and to adjust the body mass index inclusion restriction to above the 5th percentile rather than within the 5th and 95th percentile. and exclusion criteria #1, #3 and #4 were updated to exclude subjects with severe obesity including weight-related health problems, and to extend ECG screening exclusion criteria from Visit 1 to Visit 1 or pre-dose Visit 4. |
||||||
22 Apr 2020 |
Removal of reversibility criteria. Deletion of Visit 2. A window of +10 minutes added for the 30-minute post-dose ECG only. Text added allowing subjects to choose an alternate safe location for home nursing visits. Inclusion criterion #3 updated and included that the subject must have used the monotherapy at least once in the 3 months prior to screening. Screen failures section revised to allow re-screening of screen failure subjects due to not meeting reversibility criteria. Section of sample size determination was revised to increase the flexibility, that 24 eligible subjects should include 11 to 13 subjects in each age group was removed. Addition that ECG collection timing was to occur prior to vital signs when these assessments were performed at the same time. Requirement that the 24 eligible subjects should include 11 to 13 subjects in each age group was removed. Changes made to clarify PK and PD set. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |